四川路橋(600039.SH):下屬施工企業擬參股投資G5京昆高速公路成都至雅安段擴容工程
格隆匯7月22日丨四川路橋(600039.SH)公佈,下屬施工企業四川公路橋樑建設集團有限公司(簡稱路橋集團)、四川省交通建設集團有限責任公司(簡稱交建集團)以參股方式與中國華西企業股份有限公司(簡稱華西股份)及公司關聯方四川成渝高速公路股份有限公司(簡稱成渝公司)、四川高路信息科技有限公司(簡稱高路信息)組成聯合體,參與G5京昆高速公路成都至雅安段擴容工程投資。本項目總投資285.48億元,項目自籌資本金比例為20.20%,約為57.67億元。本公司持股比例為4%,其中路橋集團、交建集團分別持股1%、3%,共需投入項目資本金約為2.307億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.